Interestingly, human genome-wide association study (GWAS) data has identified the STAT5 signaling pathway as a potential modulator of cirrhosis risk in NAFLD patients (Chen et al. 2013a). This evidence concerns the gene STAT5A and metabolic dysfunction-associated steatotic liver disease.